ntellia Therapeutics announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application for NTLA-2002 for the treatment of hereditary angioedema, enabling the company to include the United States in the global Phase 2 portion of its ongoing Phase 1/2 study. NTLA-2002 is an in vivo genome editing candidate designed to inactivate the target gene, kallikrein B1, to permanently reduce plasma kallikrein protein activity and thus prevent HAE attacks after a single-dose treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $111 from $129 at Chardan
- Intellia Therapeutics price target lowered to $42 from $58 at Baird
- Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics reports Q4 EPS ($1.40), consensus ($1.39)
- Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates